Magnetic Resonance Spectroscopy Findings of Central Pontine Myelinolysis in an Alcohol Abuser

Magnetic Resonance Spectroscopy Findings of Central Pontine Myelinolysis in an Alcohol Abuser

Central pontine myelinolysis (CPM), a form of osmotic demyelination syndrome (ODS), is a neurological condition characterized by the destruction of the myelin sheath in the central pons. First described by Adams et al. in 1959, CPM is often associated with chronic alcoholism, malnutrition, liver transplantation, and rapid correction of hyponatremia. The clinical manifestations of CPM are highly variable, ranging from mild symptoms such as dysarthria and dysphagia to severe conditions like quadriparesis and locked-in syndrome. Despite its potentially devastating consequences, some cases of CPM remain asymptomatic. The diagnosis of CPM relies heavily on neuroimaging, particularly magnetic resonance imaging (MRI), which typically reveals characteristic lesions in the central pons. However, the size of these lesions does not always correlate with the severity of clinical symptoms. This article explores the role of magnetic resonance spectroscopy (MRS) in diagnosing and understanding CPM, with a focus on a case involving a chronic alcohol abuser.

Pathophysiology and Clinical Presentation of CPM

CPM is a subtype of ODS, which can also involve extrapontine regions. The exact pathogenesis of CPM remains unclear, but it is believed to result from osmotic stress on oligodendrocytes, the cells responsible for producing myelin in the central nervous system. Rapid shifts in serum osmolality, such as those occurring during the rapid correction of hyponatremia, can lead to cellular dehydration and subsequent demyelination. The central pons is particularly vulnerable due to the unique “grid-like” arrangement of oligodendrocytes in this region.

Clinically, CPM presents with a wide spectrum of symptoms, depending on the extent and location of the demyelination. Common symptoms include dysarthria (difficulty speaking), dysphagia (difficulty swallowing), ataxia (loss of coordination), and oculomotor dysfunction. In severe cases, patients may develop quadriparesis (weakness in all four limbs) or locked-in syndrome, a condition in which the patient is fully conscious but unable to move or communicate. Interestingly, some patients with CPM remain asymptomatic, and the condition is only discovered incidentally during imaging or autopsy.

Diagnostic Imaging in CPM

MRI is the gold standard for diagnosing CPM. The typical MRI findings include a trident-shaped hyperintense lesion in the central pons on T2-weighted and fluid-attenuated inversion-recovery (FLAIR) images. On T1-weighted images, the lesion appears hypointense. Gadolinium enhancement is usually absent, although peripheral enhancement may occasionally be observed. These imaging features are highly specific for CPM and help differentiate it from other pontine lesions, such as infarcts, tumors, or infections.

Despite its diagnostic utility, MRI has limitations. The size of the lesion on MRI does not always correlate with the severity of clinical symptoms. For example, some patients with large pontine lesions may have mild symptoms, while others with small lesions may present with severe neurological deficits. This discrepancy highlights the need for additional diagnostic tools, such as MRS, to provide further insights into the underlying pathophysiology of CPM.

Role of Magnetic Resonance Spectroscopy in CPM

MRS is a non-invasive imaging technique that measures the concentration of specific metabolites in the brain. It provides biochemical information that complements the anatomical details obtained from conventional MRI. In the context of CPM, MRS can reveal changes in metabolite levels that reflect neuronal loss, gliosis, and demyelination.

The key metabolites measured in MRS include N-acetylaspartate (NAA), choline (Cho), and creatine (Cr). NAA is a marker of neuronal integrity, and its reduction is indicative of neuronal loss or dysfunction. Cho is a marker of cell membrane turnover, and its elevation suggests increased membrane breakdown or gliosis. Cr serves as an internal reference, and its levels are relatively stable in most pathological conditions.

Case Report: MRS Findings in a Chronic Alcohol Abuser

A 45-year-old man with a 20-year history of chronic alcohol abuse (consuming an average of 300 mL of Chinese liquor daily) presented with slurred speech and gait disturbance lasting for two weeks. On admission, his vital signs were stable, and neurological examination revealed dysarthria, ataxia, and mild weakness in the lower extremities (Medical Research Council grade 4/5). Sensory function and bladder/bowel habits were normal.

Brain MRI showed a characteristic lesion in the central pons, which was hyperintense on T2-weighted and FLAIR images and hypointense on T1-weighted images. Gadolinium enhancement was absent. MRS of the pontine lesion revealed a decreased NAA/Cr ratio (1.58) and an increased Cho/Cr ratio (1.59). These findings are consistent with neuronal loss and gliosis, respectively.

Laboratory tests showed elevated liver enzymes (aspartate transaminase 94 U/L, alanine transaminase 45 U/L, gamma glutamyl transpeptidase 114 U/L) and mild hypokalemia (potassium 3.0 mmol/L). Blood sodium, glucose, vitamin B1, vitamin B12, and ceruloplasmin levels were within normal limits. Cerebrospinal fluid (CSF) analysis was unremarkable. Based on the patient’s history of chronic alcohol abuse and typical MRI findings, a diagnosis of CPM was made.

The patient was treated with high-dose multivitamins and nutritional support. Over the course of 22 days, his lower limb weakness improved moderately, but his dysarthria persisted. Unfortunately, follow-up MRI was not performed, limiting the ability to assess the long-term evolution of the pontine lesion.

Discussion: Implications of MRS Findings in CPM

The MRS findings in this case are consistent with previous reports of CPM. The decreased NAA/Cr ratio suggests neuronal loss or dysfunction, while the increased Cho/Cr ratio indicates gliosis or increased membrane turnover. These changes are thought to reflect the underlying pathophysiology of CPM, which involves demyelination and secondary neuronal damage.

Interestingly, the severity of the patient’s clinical symptoms did not correlate with the extent of the pontine lesion on MRI. This observation aligns with previous studies, which have found no significant relationship between lesion size and clinical severity in ODS. The MRS findings, however, provide additional insights into the biochemical changes occurring in the brain and may help explain the variability in clinical presentation.

The role of MRS in predicting outcomes in CPM remains unclear. In this case, the NAA peak was decreased but not significantly, suggesting that the majority of neurons in the pons were preserved. This may explain the patient’s moderate clinical improvement. However, more research is needed to determine whether MRS can serve as a prognostic tool in CPM.

Conclusion

CPM is a rare but potentially devastating condition that often occurs in the context of chronic alcoholism, malnutrition, or rapid correction of hyponatremia. While MRI is the primary diagnostic tool, MRS provides valuable biochemical information that complements the anatomical findings. In this case, MRS revealed decreased NAA and increased Cho levels in the pontine lesion, consistent with neuronal loss and gliosis. These findings highlight the potential utility of MRS in understanding the pathophysiology of CPM and its clinical implications. Further research is needed to explore the prognostic value of MRS in this condition.

doi.org/10.1097/CM9.0000000000000703

Was this helpful?

YesNo

0 / 0